ArticleScientific reports2021
Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Postoperative Adjuvant Transcatheter Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma: Patient Selection and Clinical Predictors of Therapeutic Benefit.Journal of hepatocellular carcinoma · 2026Review
- Case Report: Thoracic spinal metastasis without definite intrahepatic recurrence after conversion therapy and hepatectomy for hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Development and External Validation of a Multimodal Machine Learning Model Integrating Preoperative Contrast-Enhanced CT Radiomics and Clinicopathological Features for Predicting Early Extrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Pre- and postoperative predictors of extrahepatic recurrence after curative resection for hepatocellular carcinoma.BMC cancer · 2025Article
- Leave No "Stone" Unturned: Biliary Obstruction From Isolated Intraductal Metastatic HCC.ACG case reports journal · 2025Article
- Article
- Hepatocellular carcinoma presenting as an extrahepatic mass: A case report and review of literature.World journal of gastrointestinal oncology · 2024Article
- Hepatocellular carcinoma recurrence: Predictors and management.Liver research (Beijing, China) · 2023Review
- Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study.World journal of gastroenterology · 2022Observational
- [The consensus on tertiary prevention of primary liver cancer (2022 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Comparison of portal and capsular microscopic vascular invasion in the outcomes of early HCC after curative resection.American journal of cancer research · 2022Article
- Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment.Journal of hepatocellular carcinoma · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrahepatic recurrence (EHR) after curative hepatectomy for hepatocellular carcinoma (HCC) is associated with a poor prognosis. We investigated the features of EHR and identified its predictive factors. This retrospective study included 398 treatment-naive patients who underwent curative hepatectomy for HCC at two tertiary hospitals. Multivariate Cox-regression analysis was performed to identify the variables associated with EHR. EHR was diagnosed in 94 patients (23.6%) over a median follow-up period of 5.92 years, most commonly in the lungs (42.6%). The 5-/10-year cumulative rates of HCC recurrence and EHR were 63.0%/75.6% and 18.1%/35.0%, respectively. The median time to EHR was 2.06 years. Intrahepatic HCC recurrence was not observed in 38.3% of patients on EHR diagnosis. On multivariate analysis, pathologic modified Union for International Cancer Control stage (III, IVa), surgical margin involvement, tumor necrosis, sum of tumor size > 7 cm, and macrovascular invasion were predictive factors of EHR. Four risk levels and their respective EHR rates were defined as follows: very low risk, 1-/5-year, 3.1%/11.6%; low risk, 1-/5-year, 12.0%/27.7%; intermediate risk, 1-/5-year, 36.3%/60.9%; and high risk, 1-year, 100.0%. Our predictive model clarifies the clinical course of EHR and could improve the follow-up strategy to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.